MétaCan
Menu
Back to cohort
Record W4408245823 · doi:10.1093/neuonc/noaf046

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor

2025· article· en· W4408245823 on OpenAlexafffund
Alberto Delaidelli, Fares Burwag, Susana Ben‐Neriah, Yujin Suk, Taras Shyp, Suzanne Kosteniuk, Christopher Dunham, Sylvia Cheng, Konstantin Okonechnikov, Daniel Schrimpf, Andreas von Deimling, Benjamin Ellezam, Sébastien Perreault, Sheila K. Singh, Cynthia Hawkins, Marcel Kool, Stefan M. Pfister, Christian Steidl, Christopher Hughes, Andrey Korshunov, Poul H. Sorensen

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsHospital for Sick ChildrenUniversité de MontréalChildren's & Women's Health Centre of British ColumbiaBC Children's HospitalUniversity of ManitobaJuravinski Cancer CentreUniversity of British ColumbiaMcMaster University Medical CentreDalhousie UniversityHamilton Health SciencesCentre Hospitalier Universitaire Sainte-JustineMcMaster UniversitySpinal Cord Injury BCSickKids FoundationBC Cancer Agency
FundersTerry Fox Research Institute
KeywordsMedulloblastomaImmunohistochemistryOncologyBiologyInternal medicineMedicineCancer research

Abstract

fetched live from OpenAlex

BACKGROUND: While international consensus and the 2021 WHO classification recognize multiple molecular medulloblastoma subgroups, these are difficult to identify in clinical practice utilizing routine approaches. As a result, biology-driven risk stratification and therapy assignment for medulloblastoma remains a major clinical challenge. Here, we report mass spectrometry-based analysis of clinical samples for medulloblastoma subgroup discovery, highlighting a MYC-driven prognostic signature and MYC immunohistochemistry (IHC) as a clinically tractable method for improved risk stratification. METHODS: We analyzed 56 formalin fixed paraffin embedded (FFPE) medulloblastoma samples by data-independent acquisition mass spectrometry identifying a MYC proteome signature in therapy-resistant group 3 medulloblastoma. We validated MYC IHC prognostic and predictive value across 2 groups of 3/4 medulloblastoma clinical cohorts (n = 362) treated with standard therapies. RESULTS: After the exclusion of WNT tumors, MYC IHC was an independent predictor of therapy resistance and death [HRs 23.6 and 3.23; 95% confidence interval (CI) 1.04-536.18 and 1.84-5.66; P = .047 and <.001]. Notably, only ~50% of the MYC IHC-positive tumors harbored MYC amplification. Accordingly, cross-validated survival models incorporating MYC IHC outperformed current risk stratification schemes including MYC amplification, and reclassified ~20% of patients into a more appropriate very high-risk category. CONCLUSIONS: This study provides a high-resolution proteomic dataset that can be used as a reference for future biomarker discovery. Biology-driven clinical trials should consider MYC IHC status in their design. Integration of MYC IHC in classification algorithms for non-WNT tumors could be rapidly adopted on a global scale, independently of advanced but technically challenging molecular profiling techniques.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.582
Threshold uncertainty score0.802

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.350
Teacher spread0.326 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicGlioma Diagnosis and TreatmentFrench-language works237,207